Renata Ferreira Magalhães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renata Ferreira Magalhães has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Yumi Massuda Serrano
Department of Dermatology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil
9 shared publications - Rafael Fantelli Stelini
Universidade Estadual de Campinas, Brazil; Centrolab, Brazil
8 shared publications - Ariany Tomaz de Aquino Saran Denofre
Discipline of Dermatology University of Campinas ‐ Unicamp Brazil
7 shared publications - Thais Helena Buffo
Discipline of Dermatology, Medical Sciences College, Universidade Estadual de Campinas, Campinas, SP, Brazil
7 shared publications - Andrea Fernandes Eloy da Costa França
Universidade Estadual de Campinas, Brasil
6 shared publications - Dimitri Luz Felipe da Silva
University Santo Amaro, Hospital Israelita Albert Einstein, São Paulo, Brazil
6 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in JAAD Case Reports
Persistent sparing of severe atopic dermatitis within segmental vitiligo: clinicopathological evidence of a stable cutaneous immune district
- 13 November 2026
- Published by Elsevier in JAAD Case Reports
Open AccessPersistent sparing of severe atopic dermatitis within segmental vitiligo: clinicopathological evidence of a stable cutaneous immune district
- Open Access
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 652
Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
Background/Objectives: Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological adverse events (AEs). We aimed to characterize the spectrum, frequency, and clinical characteristics of cutaneous AEs reported with semaglutide, liraglutide and tirzepatide, focusing on these agents because of their established use in both weight management and diabetes mellitus. Methods: A systematic literature search was conducted in MEDLINE (via PubMed), Embase, and Web of Science. Search terms combined skin-related manifestations (e.g., skin, dermatologic, injection-site reactions, pruritus, rash, hypersensitivity, dysesthesia, vasculitis) with GLP-1 RA and GIP/GLP-1 RAs (semaglutide, tirzepatide, liraglutide). Clinical trials, observational studies, pharmacovigilance studies, and case reports reporting skin-related AEs associated with semaglutide, liraglutide and tirzepatide were included. Results: One hundred and one studies were included (32 randomized controlled trials, 6 retrospective cohort/cross-sectional studies, 20 pharmacovigilance studies, and 43 case series/reports). Cutaneous AEs ranged from generally common but mild reactions to rare but potentially severe immune-mediated disorders. Injection-site reactions, including erythema, pruritus, and hemorrhage, were reported most frequently with tirzepatide (2–7%), then liraglutide, and less commonly with semaglutide, with evidence of dose dependence. Dysesthesia was most strongly associated with semaglutide, occurring in approximately 5% of patients at standard doses and up to 20% with high-dose formulations indicated for weight management, with events frequently occurring during dose escalation. Uncommon reactions reported in association with GLP-1 or GIP/GLP-1 RA use included angioedema, hypersensitivity reactions, autoimmune blistering diseases, drug eruptions, vasculitis, and severe cutaneous reactions. Conclusions: Although most cutaneous AEs associated with GLP-1 and GIP/GLP-1 RAs are mild and manageable, clinically relevant drug-specific differences exist. The recognition of common and uncommon skin manifestations may facilitate earlier diagnosis, support treatment adherence, and reduce the adverse outcomes.
- 9 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (6) , 652
Open AccessCutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
Background/Objectives: Incretin-based therapies, including glucagon like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly prescribed for obesity, leading to greater recognition of associated dermatological adverse events (AEs). We aimed to characterize the spectrum, frequency, and clinical characteristics of cutaneous AEs reported with semaglutide, liraglutide and tirzepatide, focusing on these agents because of their established use in both weight management and diabetes mellitus. Methods: A systematic literature search was conducted in MEDLINE (via PubMed), Embase, and Web of Science. Search terms combined skin-related manifestations (e.g., skin, dermatologic, injection-site reactions, pruritus, rash, hypersensitivity, dysesthesia, vasculitis) with GLP-1 RA and GIP/GLP-1 RAs (semaglutide, tirzepatide, liraglutide). Clinical trials, observational studies, pharmacovigilance studies, and case reports reporting skin-related AEs associated with semaglutide, liraglutide and tirzepatide were included. Results: One hundred and one studies were included (32 randomized controlled trials, 6 retrospective cohort/cross-sectional studies, 20 pharmacovigilance studies, and 43 case series/reports). Cutaneous AEs ranged from generally common but mild reactions to rare but potentially severe immune-mediated disorders. Injection-site reactions, including erythema, pruritus, and hemorrhage, were reported most frequently with tirzepatide (2–7%), then liraglutide, and less commonly with semaglutide, with evidence of dose dependence. Dysesthesia was most strongly associated with semaglutide, occurring in approximately 5% of patients at standard doses and up to 20% with high-dose formulations indicated for weight management, with events frequently occurring during dose escalation. Uncommon reactions reported in association with GLP-1 or GIP/GLP-1 RA use included angioedema, hypersensitivity reactions, autoimmune blistering diseases, drug eruptions, vasculitis, and severe cutaneous reactions. Conclusions: Although most cutaneous AEs associated with GLP-1 and GIP/GLP-1 RAs are mild and manageable, clinically relevant drug-specific differences exist. The recognition of common and uncommon skin manifestations may facilitate earlier diagnosis, support treatment adherence, and reduce the adverse outcomes.
- Open Access
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Clinical practice guideline for psoriasis management in Latin America
- 29 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Open AccessClinical practice guideline for psoriasis management in Latin America
- Open Access
- 17 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Pigmented purpuric dermatoses versus purpuric mycosis fungoides: red flags from a clinicopathologic case series
- 17 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5)
Open AccessPigmented purpuric dermatoses versus purpuric mycosis fungoides: red flags from a clinicopathologic case series
- Open Access
- 7 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501444
Metabolic, inflammatory and subclinical endothelial alterations in patients with moderate-to-severe psoriasis: an investigation letter
- 7 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501444
Open AccessMetabolic, inflammatory and subclinical endothelial alterations in patients with moderate-to-severe psoriasis: an investigation letter
- Open Access
- 3 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501447
The new metrics of Anais Brasileiros de Dermatologia
- 3 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501447
Open AccessThe new metrics of Anais Brasileiros de Dermatologia
- Open Access
- 27 June 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (4) , 501402
The intergluteal cleft lesion in hidradenitis suppurativa: clinical characteristics and potential clinical implications
- 27 June 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (4) , 501402
Open AccessThe intergluteal cleft lesion in hidradenitis suppurativa: clinical characteristics and potential clinical implications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59, e0276
Brazil accounts for nearly 90% of the leprosy cases in the Americas
Background: Leprosy is endemic to Brazil. The Coronavirus disease 2019 (COVID-19) pandemic may have affected diagnosis and treatment. Methods: Study in Mossoró-RN (2018-2023) analyzing epidemiological data, treatment abandonment, and COVID-19 co-infection. Results: The average weekly number of cases declined during the post-pandemic period. The dropout rate was higher during the acute phase. Male sex was associated with dropout (odds ratio [OR], 6.32; p = 0.013). Of the 57 patients tested for COVID-19, 21 tested positive, with no clinical aggravation. Conclusions: The pandemic has affected leprosy control. Local strategies helped reduce the impact, and co-infection did not worsen the disease.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59, e0276
Open AccessBrazil accounts for nearly 90% of the leprosy cases in the Americas
Background: Leprosy is endemic to Brazil. The Coronavirus disease 2019 (COVID-19) pandemic may have affected diagnosis and treatment. Methods: Study in Mossoró-RN (2018-2023) analyzing epidemiological data, treatment abandonment, and COVID-19 co-infection. Results: The average weekly number of cases declined during the post-pandemic period. The dropout rate was higher during the acute phase. Male sex was associated with dropout (odds ratio [OR], 6.32; p = 0.013). Of the 57 patients tested for COVID-19, 21 tested positive, with no clinical aggravation. Conclusions: The pandemic has affected leprosy control. Local strategies helped reduce the impact, and co-infection did not worsen the disease.
- Open Access
- 11 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 193-198
When hidradenitis suppurativa flares mimic sepsis: A case series of 6 hospitalized patients
- 11 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 193-198
Open AccessWhen hidradenitis suppurativa flares mimic sepsis: A case series of 6 hospitalized patients
- Open Access
- 23 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Inteligência artificial em dermatoses inflamatórias: onde estamos e para onde vamos?
- 23 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Open AccessInteligência artificial em dermatoses inflamatórias: onde estamos e para onde vamos?